Liver enzyme trends in patients taking uninterrupted metformin before and after coronary surgery | Zendy

Rakan Nazer | Zendy; Mohammed Abalhassan | Zendy; Khalid A. Alburikan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Liver enzyme trends in patients taking uninterrupted metformin before and after coronary surgery

Author(s) -

Rakan Nazer,

Mohammed Abalhassan,

Khalid A. Alburikan

Publication year - 2018

Publication title -

cardiovascular diagnosis and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.83

H-Index - 22

eISSN - 2223-3660

pISSN - 2223-3652

DOI - 10.21037/cdt.2018.05.04

Subject(s) - medicine , metformin , biguanide , interquartile range , diabetes mellitus , alanine transaminase , aspartate transaminase , creatinine , surgery , alanine aminotransferase , gastroenterology , endocrinology , enzyme , alkaline phosphatase , biochemistry , chemistry

Metformin is an oral antidiabetic agent belonging to the biguanide class of antidiabetics. Possible novel applications for metformin in cardiovascular disease might exist. The aim of this study was to verify a possible association between pre-operative metformin administration and protection against ischemia-induced liver injury in diabetic patients undergoing coronary artery bypass grafting (CABG) surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research